Molecular Phenotyping Combines Molecular Information, Biological Relevance, and Patient Data to Improve Productivity of Early Drug Discovery

Cell Chemical Biology

Volumn 24, Issue 5, 2017, Pages 624-634.e3

  Drawnel, Faye Marie ^a   Zhang, Jitao David ^a   Küng, Erich ^a   Aoyama, Natsuyo ^b   Benmansour, Fethallah ^a   Araujo Del Rosario, Andrea ^a   Jensen Zoffmann, Sannah ^a   Delobel, Frédéric ^a   Prummer, Michael ^a,c   Weibel, Franziska ^a   Carlson, Coby ^b   Anson, Blake ^b   Iacone, Roberto ^a   Certa, Ulrich ^a   Singer, Thomas ^a   Ebeling, Martin ^a   Prunotto, Marco ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Cellular Dynamics International   (United States)

^c ETH ZURICH   (Switzerland)

Author keywords

calcium signaling; cardiomyocytes; drug discovery; high throughput RNA sequencing; molecular phenotypic screening; pathway reporters

Indexed keywords

10 HYDROXYCAMPTOTHECIN; BETA CATENIN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ENDOTHELIN 1; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOPERAMIDE; LYCORINE; MIFEPRISTONE; NICARDIPINE; NIGERICIN; NIGULDIPINE; PROGESTERONE RECEPTOR; TOPOTECAN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ARTICLE; BINDING AFFINITY; CALCIUM SIGNALING; CLINICAL ASSESSMENT; DIABETIC CARDIOMYOPATHY; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG SCREENING; FALSE POSITIVE RESULT; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR BIOLOGY; MOLECULAR PHENOTYPING; PATIENT CODING; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN BINDING; REPORTER GENE; SCREENING TEST; BIOLOGY; DATA MINING; PHENOTYPE; PRECLINICAL STUDY; PROCEDURES;

COMPUTATIONAL BIOLOGY; DATA MINING; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; PHENOTYPE;

EID: 85018611617     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.03.016     Document Type: Article

References (42)

1. Afzal, N., Ganguly, P.K., Dhalla, K.S., Pierce, G.N., Singal, P.K., Dhalla, N.S., Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37 (1988), 936–942.
2. Aronsen, J.M., Louch, W.E., Sjaastad, I., Cardiomyocyte Ca2+ dynamics: clinical perspectives. Scand. Cardiovasc. J. 50 (2016), 65–77.
3. Belke, D.D., Swanson, E.A., Dillmann, W.H., Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53 (2004), 3201–3208.
4. Chen, J., Cha-Molstad, H., Szabo, A., Shalev, A., Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am. J. Physiol. Endocrinol. Metab. 296 (2009), E1133–E1139.
5. Chen, S., Jin, G., Huang, K.M., Ma, J.J., Wang, Q., Ma, Y., Tang, X.Z., Zhou, Z.J., Hu, Z.J., Wang, J.Y., et al. Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo. Sci. Rep., 5, 2015, 12853.
6. Darzacq, X., Shav-Tal, Y., de Turris, V., Brody, Y., Shenoy, S.M., Phair, R.D., Singer, R.H., In vivo dynamics of RNA polymerase II transcription. Nat. Struct. Mol. Biol. 14 (2007), 796–806.
7. Drawnel, F.M., Wachten, D., Molkentin, J.D., Maillet, M., Aronsen, J.M., Swift, F., Sjaastad, I., Liu, N., Catalucci, D., Mikoshiba, K., et al. Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy. J. Cell Biol. 199 (2012), 783–798.
8. Drawnel, F.M., Boccardo, S., Prummer, M., Delobel, F., Graff, A., Weber, M., Gerard, R., Badi, L., Kam-Thong, T., Bu, L., et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 9 (2014), 810–821.
9. Edgar, R., Domrachev, M., Lash, A.E., Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:1 (2002), 207–210.
10. Franz, W.M., Muller, O.J., Katus, H.A., Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358 (2001), 1627–1637.
11. Gao, H., Wang, F., Wang, W., Makarewich, C.A., Zhang, H., Kubo, H., Berretta, R.M., Barr, L.A., Molkentin, J.D., Houser, S.R., Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling. J. Mol. Cell Cardiol. 53 (2012), 657–667.
12. Green, R.C., Goddard, K.A., Jarvik, G.P., Amendola, L.M., Appelbaum, P.S., Berg, J.S., Bernhardt, B.A., Biesecker, L.G., Biswas, S., Blout, C.L., et al. Clinical Sequencing Exploratory Research Consortium: accelerating evidence-based practice of genomic medicine. Am. J. Hum. Genet. 98 (2016), 1051–1066.
13. Groenendyk, J., Agellon, L.B., Michalak, M., Coping with endoplasmic reticulum stress in the cardiovascular system. Annu. Rev. Physiol. 75 (2013), 49–67.
14. Haibe-Kains, B., El-Hachem, N., Birkbak, N.J., Jin, A.C., Beck, A.H., Aerts, H.J., Quackenbush, J., Inconsistency in large pharmacogenomic studies. Nature 504 (2013), 389–393.
15. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat. Biotechnol. 32 (2014), 40–51.
16. Higazi, D.R., Fearnley, C.J., Drawnel, F.M., Talasila, A., Corps, E.M., Ritter, O., McDonald, F., Mikoshiba, K., Bootman, M.D., Roderick, H.L., Endothelin-1-stimulated InsP3-induced Ca2+ release is a nexus for hypertrophic signaling in cardiac myocytes. Mol. Cell 33 (2009), 472–482.
17. Hileeto, D., Cukiernik, M., Mukherjee, S., Evans, T., Barbin, Y., Downey, D., Karmazyn, M., Chakrabarti, S., Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab. Res. Rev. 18 (2002), 386–394.
18. Hu, M., Peng, S., He, Y., Qin, M., Cong, X., Xing, Y., Liu, M., Yi, Z., Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer. Oncotarget 6 (2015), 15348–15361.
19. Huang, H., Joseph, L.C., Gurin, M.I., Thorp, E.B., Morrow, J.P., Extracellular signal-regulated kinase activation during cardiac hypertrophy reduces sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) transcription. J. Mol. Cell Cardiol. 75 (2014), 58–63.
20. Kerkela, R., Kockeritz, L., Macaulay, K., Zhou, J., Doble, B.W., Beahm, C., Greytak, S., Woulfe, K., Trivedi, C.M., Woodgett, J.R., et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J. Clin. Invest. 118 (2008), 3609–3618.
21. Khanna, I., Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov. Today 17 (2012), 1088–1102.
22. Lamoral-Theys, D., Decaestecker, C., Mathieu, V., Dubois, J., Kornienko, A., Kiss, R., Evidente, A., Pottier, L., Lycorine and its derivatives for anticancer drug design. Mini Rev. Med. Chem. 10 (2010), 41–50.
23. Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., Tamayo, P., The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1 (2015), 417–425.
24. Lim, J.Y., Park, S.J., Hwang, H.Y., Park, E.J., Nam, J.H., Kim, J., Park, S.I., TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J. Mol. Cell Cardiol. 39 (2005), 627–636.
25. Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D., Woolf, P.J., GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics, 10, 2009, 161.
26. Matsuda, T., Zhai, P., Maejima, Y., Hong, C., Gao, S., Tian, B., Goto, K., Takagi, H., Tamamori-Adachi, M., Kitajima, S., et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc. Natl. Acad. Sci. USA 105 (2008), 20900–20905.
27. Mignani, S., Huber, S., Tomas, H., Rodrigues, J., Majoral, J.P., Why and how have drug discovery strategies in pharma changed? What are the new mindsets?. Drug Discov. Today 21 (2016), 239–249.
28. Morris, E.J., Geller, H.M., Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell Biol. 134 (1996), 757–770.
29. Pereira, L., Matthes, J., Schuster, I., Valdivia, H.H., Herzig, S., Richard, S., Gomez, A.M., Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55 (2006), 608–615.
30. Pereira, L., Ruiz-Hurtado, G., Rueda, A., Mercadier, J.J., Benitah, J.P., Gomez, A.M., Calcium signaling in diabetic cardiomyocytes. Cell Calcium 56 (2014), 372–380.
31. Robinson, M.D., McCarthy, D.J., Smyth, G.K., edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2010), 139–140.
32. Scannell, J.W., Bosley, J., When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS One, 11, 2016, e0147215.
33. Singh, J., Padgett, R.A., Rates of in situ transcription and splicing in large human genes. Nat. Struct. Mol. Biol. 16 (2009), 1128–1133.
34. Steuer, C.E., Papadimitrakopoulou, V., Herbst, R.S., Redman, M.W., Hirsch, F.R., Mack, P.C., Ramalingam, S.S., Gandara, D.R., Innovative clinical trials: the LUNG-MAP study. Clin. Pharmacol. Ther. 97 (2015), 488–491.
35. Storey, J., The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Stat. 31 (2003), 2013–2035.
36. Tuomilehto, J., Rastenyte, D., Birkenhager, W.H., Thijs, L., Antikainen, R., Bulpitt, C.J., Fletcher, A.E., Forette, F., Goldhaber, A., Palatini, P., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 340 (1999), 677–684.
37. Waring, M.J., Arrowsmith, J., Leach, A.R., Leeson, P.D., Mandrell, S., Owen, R.M., Pairaudeau, G., Pennie, W.D., Pickett, S.D., Wang, J., et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. 14 (2015), 475–486.
38. Xi, X.H., Wang, Y., Li, J., Wang, F.W., Tian, G.H., Yin, M.S., Mu, Y.L., Chong, Z.Z., Activation of Wnt/beta-catenin/GSK3beta signaling during the development of diabetic cardiomyopathy. Cardiovasc. Pathol. 24 (2015), 179–186.
39. Zhang, J.D., Berntenis, N., Roth, A., Ebeling, M., Data mining reveals a network of early-response genes as a consensus signature of drug-induced in vitro and in vivo toxicity. Pharmacogenomics J. 14 (2014), 208–216.
40. Zhang, J.D., Schindler, T., Küng, E., Ebeling, M., Certa, U., Highly sensitive amplicon-based transcript quantification by semiconductor sequencing. BMC genomics, 15(1), 2014, 565.
41. Zhang, J.D., Küng, E., Boess, F., Certa, U., Ebeling, M., Pathway reporter genes define molecular phenotypes of human cells. BMC genomics, 16(1), 2015, 342.
42. Zhang, X., Ai, X., Nakayama, H., Chen, B., Harris, D.M., Tang, M., Xie, Y., Szeto, C., Li, Y., Zhang, H., et al. Persistent increases in Ca(2+) influx through Cav1.2 shortens action potential and causes Ca(2+) overload-induced afterdepolarizations and arrhythmias. Basic Res. Cardiol., 111, 2016, 4.